RenovoRx, Inc. (NasdaqCM: RNXT)
Health Care · Biotechnology · US
$1.14
-10.94% today · -5.0% 1Y
RenovoRx, Inc. (NasdaqCM: RNXT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $51.45M and employs 17 people.
Over the last twelve months the share price has lost 5.0%, trading between 0.70 and 2.59.
Tweenvest scores RenovoRx, Inc. across four factors: quality 46/100, value 80/100. Its strongest factor is value.
RNXT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.45M
- Revenue (TTM)
- $1.98M
- P/E
- —
- EPS
- -0.31
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- $2.59
- 52-week low
- $0.70
- Avg volume (3M)
- —
- Shares outstanding
- 45.13M
- Employees
- 17
- Next earnings
- —
About RenovoRx, Inc.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
- ISIN
- US75989R1077
- Founded
- 2009
- Listed since
- Aug 26, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sirnaomics Ltd.SEHK: 2257 | $52.66M | HK$3.80 | +1.34% |
| UBI Pharma Inc.UNQ: 6562 | $52.10M | NT$— | — |
| CG Invites Co., Ltd.KOSDAQ: A083790 | $52.02M | ₩902.00 | -3.01% |
| CellSeed Inc.TSE: 7776 | $51.50M | ¥206.00 | -2.37% |
| Synbio Tech Inc.TPEX: 1295 | $51.37M | NT$48.35 | -3.49% |
| Prestige BioPharma LimitedKOSE: A950210 | $51.30M | ₩5,690.00 | -4.53% |
| Nano Holdings, Inc.TSE: 4571 | $51.13M | ¥89.00 | +12.66% |
| Uni-Bio Science Group LimitedSEHK: 690 | $50.98M | HK$0.07 | -4.29% |
Figures last refreshed Oct 18, 2026.